cilastatin sodium; imipenem · Merck · NDA 050587, 050630
Primaxin
Earliest generic entry, as listed
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 050587 · 001 · RLD · discontinued | powder, intravenous | EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 050587 · 002 · RLD | powder, intravenous | EQ 500MG BASE/VIAL;500MG/VIAL | open |
| 050630 · 001 · discontinued | powder, intramuscular | EQ 500MG BASE/VIAL;500MG/VIAL | open |
| 050630 · 002 · discontinued | powder, intramuscular | EQ 750MG BASE/VIAL;750MG/VIAL | open |